Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
Jay S. Cooper(Columbia University Irving Medical Center), Karen K. Fu(University of California, San Francisco), Christopher J. Schultz(Medical College of Wisconsin), Scott Saxman(Eastern Cooperative Oncology Group), John F. Ensley(Wayne State University), Bruce H. Campbell(Medical College of Wisconsin), K. S. Clifford Chao(The University of Texas MD Anderson Cancer Center), Mitchell Machtay(University of Pennsylvania Health System), Thomas F. Pajak(American College of Radiology), Anthony J. Cmelak(Breast Cancer Research Foundation), Nancy Y. Lee(Memorial Sloan Kettering Cancer Center), Marvin Rotman(State University of New York), Julie A. Kish(Moffitt Cancer Center), Arlene A. Forastiere(Greater Baltimore Medical Center), Harold E. Kim(Wayne State University)
Cited by 3,249
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k